Key result
Neuroleptic malignant syndrome is a rare, potentially fatal adverse reaction to antipsychotics that requires early recognition, immediate discontinuation of the offending agent, and supportive care.
Why the study?
Neuroleptic malignant syndrome is a rare, potentially fatal adverse drug reaction whose subtle forms are difficult to recognize because of symptom overlap with other conditions.
Neuroleptic malignant syndrome is a medical emergency requiring prompt recognition and management in an acute hospital setting.
Neuroleptic malignant syndrome demands prompt acute hospital care; this review leaves open needs for prospective trials on standardized management.
SUMMARY Neuroleptic malignant syndrome (NMS) is a rare and potentially fatal adverse reaction to drugs. In psychiatric practice, it is mainly associated with antipsychotics. The classic presentation is that of hyperpyrexia, muscle rigidity, mental state changes and autonomic instability. Subtle forms are difficult to recognise owing to symptom overlap with other conditions. This article discusses the clinical presentation of the syndrome, its differential diagnosis and use of supportive care, medication and electroconvulsive therapy in its treatment. It also explores prevention of NMS and reinstatement of treatment after an episode. It is stressed that all but the mildest forms of NMS should be considered a medical emergency that is properly managed in an acute hospital.
No takes yet. Share an insight, caveat, or question.
Wadoo et al. (2020) conducted a review in Neuroleptic malignant syndrome. Antipsychotics was evaluated. Neuroleptic malignant syndrome is a rare, potentially fatal adverse reaction to antipsychotics that requires early recognition, immediate discontinuation of the offending agent, and supportive care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: